Stimcell Energetics Pivots on eBalance Amidst Funding Woes

TL;DR

**Stimcell Energetics is a high-risk speculative play, betting on a successful eBalance redesign and future funding after a significant R&D pause.**

AI Summary

Stimcell Energetics Inc. (STME) filed its 10-K for the fiscal year ended May 31, 2025, revealing a strategic pivot and significant financial challenges. The company completed a 1-for-15 reverse stock split on November 1, 2024, decreasing outstanding shares from 297,236,373 to 19,816,272 and changing its name from Cell MedX Corp. The primary focus remains on its eBalance Technology, a microcurrent electrical therapy device for general wellness and pain relief, initially targeting diabetes complications. However, due to financial constraints, STME suspended further research and development of eBalance Technology and defaulted on its Health Canada Class II Medical Device System Certification licenses on June 5, 2023. In February 2025, a new partnership with ADM Tronics Unlimited, Inc. was established to redesign the eBalance Home device into a more compact, affordable consumer unit with advanced diagnostic features. The company's aggregate market value of common equity held by non-affiliates was $5,909,613 as of November 30, 2024, with 20,516,272 shares outstanding as of August 29, 2025.

Why It Matters

Stimcell Energetics' 10-K reveals a company at a critical juncture, attempting to revive its core eBalance technology after suspending R&D due to financial instability. For investors, the partnership with ADM Tronics Unlimited, Inc. offers a glimmer of hope for a more viable product, but the past suspension of Health Canada certifications and ongoing funding challenges signal high risk. Employees face uncertainty given the prior R&D halt, while potential customers for the eBalance Home System could benefit from a redesigned, more affordable device if the company secures necessary financing. In the competitive biotech space, STME's ability to execute on this redesign and re-enter the market will be a key determinant of its future, especially given the large and growing diabetes care market.

Risk Assessment

Risk Level: high — The risk level is high due to the company's explicit statement of 'lack of funding and unfavorable financial position' leading to the suspension of all further research and development of eBalance Technology and defaulting on Health Canada Class II Medical Device System Certification licenses on June 5, 2023. The filing also states, 'As of the date of this Annual Report on Form 10-K, the Company is unable to provide any assurance that its attempts to raise additional capital will be successful,' indicating significant going concern risks.

Analyst Insight

Investors should approach STME with extreme caution, recognizing the significant financial and operational hurdles. Monitor closely for concrete announcements regarding successful capital raises and tangible progress on the eBalance Home device redesign with ADM Tronics Unlimited, Inc. before considering any investment.

Key Numbers

• $5,909,613 — Aggregate Market Value of Non-Affiliate Common Equity (As of November 30, 2024, reflecting the company's market capitalization.)
• 20,516,272 — Common Shares Outstanding (As of August 29, 2025, after a 1-for-15 reverse stock split.)
• 1-for-15 — Reverse Stock Split Ratio (Completed on November 1, 2024, significantly reducing outstanding shares.)
• 537 million — Adults Living with Diabetes Worldwide (In 2021, according to IDF, highlighting the large target market for eBalance Technology.)
• 783 million — Projected Adults Living with Diabetes Worldwide (By 2045, indicating a growing market opportunity for diabetes management solutions.)
• June 5, 2023 — Date of Health Canada License Suspension (Signifies a major setback due to financial difficulties, impacting product marketability.)
• February 2025 — Date of New Partnership Establishment (With ADM Tronics Unlimited, Inc. for eBalance Home redesign, indicating a renewed strategic effort.)

Key Players & Entities

• Stimcell Energetics Inc. (company) — registrant, formerly Cell MedX Corp.
• Cell MedX Corp. (company) — former name of Stimcell Energetics Inc.
• ADM Tronics Unlimited, Inc. (company) — new partner for eBalance Home device redesign
• Health Canada (regulator) — issued and then suspended Class II Medical Device System Certifications
• SEC (regulator) — Securities and Exchange Commission
• $5,909,613 (dollar_amount) — aggregate market value of common equity held by non-affiliates as of November 30, 2024
• 20,516,272 (dollar_amount) — shares of common stock outstanding as of August 29, 2025
• International Diabetes Federation (company) — source of diabetes statistics
• Nutrasource Diagnostics Inc. (company) — engaged for Clinical Study in fiscal 2016
• Dr. Richard Tytus (person) — Lead Investigator for Clinical Study

FAQ

Risk Factors

• Failure to Maintain Regulatory Compliance [high — regulatory]: The company defaulted on its Health Canada Class II Medical Device System Certification licenses on June 5, 2023, due to financial constraints. This failure impacts the marketability and regulatory approval of its eBalance Technology devices, posing a significant risk to commercialization efforts.
• Dependence on Future Funding [high — financial]: The company has a history of financial challenges, including suspending R&D due to financial constraints. Its ability to continue operations and develop its eBalance Technology is contingent upon securing future financing, which is not guaranteed.
• Reliance on Strategic Partnerships [medium — operational]: The company's renewed strategy relies heavily on a new partnership with ADM Tronics Unlimited, Inc. to redesign the eBalance Home device. The success of this partnership is critical for product development and market entry, and any failure in this collaboration poses a substantial operational risk.
• Market Acceptance of eBalance Technology [medium — market]: While the company targets a large market of adults living with diabetes (537 million in 2021, projected to 783 million by 2045), the success of eBalance Technology depends on its ability to demonstrate clear efficacy and gain market acceptance against existing solutions.
• Reverse Stock Split Impact [low — financial]: The company completed a 1-for-15 reverse stock split on November 1, 2024, reducing outstanding shares from 297,236,373 to 19,816,272. While intended to improve share price, such splits can sometimes be perceived negatively by investors and may not address underlying business challenges.

Industry Context

Stimcell Energetics Inc. operates in the health and wellness technology sector, specifically targeting the diabetes management and pain relief markets. This market is large and growing, with an estimated 537 million adults living with diabetes worldwide in 2021, projected to reach 783 million by 2045. The competitive landscape includes established medical device companies and emerging biotech firms offering various therapeutic and diagnostic solutions.

Regulatory Implications

The default on Health Canada Class II Medical Device System Certification licenses on June 5, 2023, presents a significant regulatory hurdle. Re-establishing and maintaining such certifications is critical for market access and commercialization of the eBalance devices, and failure to do so poses a substantial risk.

What Investors Should Do

1. Monitor progress of the ADM Tronics partnership
2. Assess financial health and funding needs
3. Evaluate regulatory compliance status

Key Dates

• 2024-11-01: Completion of 1-for-15 Reverse Stock Split and Name Change — Reduced outstanding shares from 297,236,373 to 19,816,272 and changed name from Cell MedX Corp. to Stimcell Energetics Inc., signaling a corporate restructuring.
• 2025-02-01: Establishment of Partnership with ADM Tronics Unlimited, Inc. — Initiated a strategic collaboration to redesign the eBalance Home device into a more compact, affordable consumer unit with advanced diagnostic features, representing a renewed development effort.
• 2023-06-05: Default on Health Canada Class II Medical Device System Certification Licenses — Indicates a significant regulatory setback and operational challenge due to financial difficulties, impacting product marketability.

Glossary

eBalance Technology

Proprietary microcurrent electrical therapy (MET) technology designed to deliver subsensory micro amperage current to support general wellness or provide temporary pain relief, with a focus on managing complications related to diabetes. (This is the core technology of Stimcell Energetics Inc., central to its product development and commercialization strategy.)

Microcurrent Electrical Therapy (MET)

A type of therapy that uses low-level electrical currents to stimulate cellular activity and promote healing or pain relief. (The scientific basis for the company's eBalance Technology.)

Reverse Split

A corporate action where a company reduces the total number of its outstanding shares by consolidating them, typically to increase the share price. (Stimcell Energetics Inc. underwent a 1-for-15 reverse split on November 1, 2024, significantly altering its share structure.)

Class II Medical Device System Certification

A regulatory classification and certification required by Health Canada for medical devices that pose a moderate risk to the user. (The company defaulted on these licenses for its eBalance devices, highlighting regulatory hurdles.)

Year-Over-Year Comparison

Information comparing key metrics to the previous year, such as revenue growth, margin changes, and new risks, is not available in the provided text. The filing details a reverse stock split and name change effective November 1, 2024, and a partnership established in February 2025, indicating significant recent strategic shifts and operational events that would likely show material changes from a prior period.

Key Financial Figures

• $0.001 — ction 12(g) of the Act: Common Stock - $0.001 par value (Title of Class) Indicate
• $0 — hares of common stock with par value of $0.001, of which 297,236,373 shares were o

Filing Documents

• stme-20250531_10k.htm (10-K) — 735KB
• stme_ex1080.htm (EX-10.80) — 9KB
• stme_ex1081.htm (EX-10.81) — 10KB
• stme_ex1082.htm (EX-10.82) — 9KB
• stme_ex1083.htm (EX-10.83) — 9KB
• stme_ex311.htm (EX-31.1) — 6KB
• stme_ex312.htm (EX-31.2) — 6KB
• stme_ex321.htm (EX-32.1) — 3KB
• stme_ex322.htm (EX-32.2) — 3KB
• stme10k_1.jpg (GRAPHIC) — 32KB
• stme10k_2.jpg (GRAPHIC) — 7KB
• stme10k_3.jpg (GRAPHIC) — 10KB
• 0001139020-25-000287.txt ( ) — 3157KB
• stme-20250531_cal.xml (EX-101.CAL) — 20KB
• stme-20250531_def.xml (EX-101.DEF) — 78KB
• stme-20250531_lab.xml (EX-101.LAB) — 158KB
• stme-20250531_pre.xml (EX-101.PRE) — 148KB
• stme-20250531.xsd (EX-101.SCH) — 36KB
• stme-20250531_10k_htm.xml (XML) — 326KB

Business

Item 1. Business. 1

Risk Factors

Item 1A. Risk Factors. 10

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments. 14

Properties

Item 2. Properties. 14

Legal Proceedings

Item 3. Legal Proceedings. 14

Mine Safety Disclosures

Item 4. Mine Safety Disclosures. 14 Part II 15

Market for Registrant ' s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant ' s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. 15

Selected Financial Data

Item 6. Selected Financial Data. 16

Management ' s Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management ' s Discussion and Analysis of Financial Condition and Results of Operations. 16

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk. 20

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data. 20

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. 21

Controls and Procedures

Item 9A. Controls and Procedures. 21

Other Information

Item 9B. Other Information 22 Part III 23

Directors, Executive Officers, and Corporate Governance

Item 10. Directors, Executive Officers, and Corporate Governance. 23

Executive Compensation

Item 11. Executive Compensation. 26

Security Ownership of Certain Beneficial Holders and Management

Item 12. Security Ownership of Certain Beneficial Holders and Management. 27

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence. 29

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services 32

Exhibits, Financial Statements Schedules

Item 15. Exhibits, Financial Statements Schedules 32

Signatures

Signatures 38 iii PART I

FORWARD LOOKING STATEMENTS

FORWARD LOOKING STATEMENTS Unless the context otherwise requires, all references in this report to "Stimcell Energetics," "the Company," "we," "us," or "our" are to Stimcell Energetics Inc. (formerly, Cell MedX Corp.), collectively with its wholly owned subsidiary Cell MedX (Canada) Corp. The information in this Annual Report contains forward-looking statements. These forward-looking statements involve risks and uncertainties, including statements regarding our capital needs, business strategy and expectations. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, the reader can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms or other comparable terminology. Actual events or results may differ materially. In evaluating these statements, the reader is urged to consider various factors, including the risks outlined from time to time, in other reports the Company files with the Securities and Exchange Commission. The forward-looking statements in this Form 10-K for the fiscal year ended May 31, 2025, are subject to risks and uncertainties that could cause actual results to differ materially from the results expressed in or implied by the statements contained in this report. As a result, the identification and interpretation of data and other information and their use in developing and selecting assumptions from and among reasonable alternatives requires the exercise of judgment. To the extent that the assumed events do not occur, the outcome may vary substantially from anticipated or projected results, and accordingly, no opinion is expressed on the achievability of those forward-looking statements. No assurance can be given that any of the assumptions relating to the forward-looking statements specified in the followi

BUSINESS

ITEM 1. BUSINESS. GENERAL Stimcell Energetics Inc. was incorporated under the laws of the State of Nevada on March 19, 2010. On April 26, 2016, the Company formed its wholly owned subsidiary, Cell MedX (Canada) Corp., (the "Subsidiary") under the laws of the Province of British Columbia. Effective November 1, 2024, the Company completed a 1-for-15 reverse split (the "Reverse Split") of its common stock. As a result of the Reverse Split, the Company's authorized capital was decreased from 7,500,000,000 shares of common stock with par value of $0.001, of which 297,236,373 shares were outstanding immediately prior to the Reverse Split, to 500,000,000 shares of common stock with par value of $0.001, of which 19,816,272 were outstanding. All share and per-share amounts in this Annual Report on Form 10-K have been retrospectively adjusted. Concurrent with the Reverse Split, the Company amended its articles of incorporation to change the Company's name from "Cell MedX Corp." to "Stimcell Energetics Inc." (the "Name Change"). Stimcell Energetics Inc. is a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness and alleviate health complications, including, but not limited to: aging, insulin sensitivity, high blood pressure, neuropathy and kidney function. The Company's primary focus is on continued research and development of its eBalance Technology and its eBalance Home System. 1 BUSINESS OF STIMCELL eBalance Technology The Company acquired its proprietary microcurrent technology designed to be used in the treatment of diabetes and related ailments (the "eBalance Technology") in 2014 through a Technology Purchase Agreement. eBalance Technology is based on the science of bioelectric signals, their effect on epigenetic events within the human body, and ability to modify and affect the behavior of cells, tissues, and organs. The eBalance Techno

View Full Filing

View this 10-K filing on SEC EDGAR